X (Twitter) LinkedIn
    Tuesday, November 28
    Login
    0 Shopping Cart
    X (Twitter) LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals & Transactions»Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug
    Deals & Transactions

    Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug

    March 3, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Germany’s Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.

    Under the terms of the licensing deal, Merck will pay Debiopharm 188 million euros upfront and has agreed to further regulatory and commercial milestones worth up to 710 million euros, as well as royalties.

    Results of a mid-stage study found Xevinapant together with chemoradiotherapy cut the risk of death by 51% compared to the current standard of care, Merck said.

    Read more at: Reuters

    By Caroline Copley and Riham Alkousaa

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    deals
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Animal drugs maker Dechra agrees to lower £4.5bn takeover by Swedish private equity firm EQT

    June 3, 2023

    Warburg and Advent in the lead to acquire Baxter’s biopharma unit

    May 13, 2023

    BlackRock Sells Asset-Backed Bonds From Credit Suisse’s Books

    April 14, 2023

    KKR buys stake in communications firm FGS Global

    April 11, 2023

    Comments are closed.

    Other Articles

    Australia’s AMP confirms in talks to sell investment management unit

    April 19, 2022

    CVS Health launches USD100m venture fund

    May 2, 2021

    Meggitt presses ahead and publishes documents for Parker-Hannifin £6.3bn takeover bid

    August 16, 2021

    Astro Aerospace to acquire Horizon Aircraft

    May 2, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    X (Twitter) LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?